Skip to contentSkip to filters

We use cookies for analytics.

Research grant

CRI Clinical Innovator

Cancer Research Institute

  • Up to $1,000,000
  • Worldwide
  • Apply directly
  • Oncology, Immunology and
Related content

About

Funding for investigator-initiated phase I/II or phase II cancer immunotherapy clinical trials designed and led by academic researchers. The programme emphasises novel immunotherapy approaches, mechanistic investigation of clinical response and the discovery or validation of predictive biomarkers, and favours studies that integrate standardised sample collection, correlative assays and advanced data analysis. Proposals on immunotherapy for chordoma can be co-funded with the Chordoma Foundation. An initial protocol concept is followed by an invited full proposal with the protocol.

Topics

Eligibility

Covers: Up to US$1 million per trial, paid against milestones, for investigator salary, patient costs, supplies, correlative assays and data analysis; indirect costs of up to 10% are provided in addition.

Medical schools or research centres in the United States or abroad; for-profit institutions are not supported.

Nationality or residence: No citizenship restrictions.

cancerresearch.org

The applicant must be the principal investigator of the proposed study. There are no citizenship restrictions, and the research may be conducted at medical schools or research centres in the United States or abroad, but not at for-profit institutions. The initial protocol concept is due 1 December 2026; invited full proposals are due 1 April 2027.

Source: cancerresearch.org